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ABSTRACT
The ﬁeld of prediagnostic Parkinson’s disease (PD) is fast
moving with an expanding range of clinical and
laboratory biomarkers, and multiple strategies seeking to
discover those in the earliest stages or those ‘at risk’. It
is widely believed that the highest likelihood of securing
neuroprotective beneﬁt from drugs will be in these
subjects, preceding current point of diagnosis of PD. In
this review, we outline current knowledge of the
prediagnostic phase of PD, including an up-to-date
review of risk factors (genetic and environmental), their
relative inﬂuence, and clinical features that occur prior to
diagnosis. We discuss imaging markers across a range of
modalities, and the emerging literature on ﬂuid and
peripheral tissue biomarkers. We then explore current
initiatives to identify individuals at risk or in the earliest
stages that might be candidates for future clinical trials,
what we are learning from these initiatives, and how
these studies will bring the ﬁeld closer to realistically
commencing primary or secondary preventive trials for
PD. Further progress in this ﬁeld hinges on greater
clinical and biological description, and understanding of
the prediagnostic, peridiagnostic and immediate
postdiagnostic stages of PD. Identifying subjects 3–
5 years before they are currently diagnosed may be an
ideal group for neuroprotective trials. At the very least,
these initiatives will help clarify the stage before and
around diagnosis, enabling the ﬁeld to push into
unchartered territory at the earliest stages of disease.
INTRODUCTION
The motor features of Parkinson’s disease (PD)
(tremor, rigidity, slowness and balance problems)
are identiﬁed relatively late in the pathological
process when approximately 50% of dopaminergic
neurons have been lost in the substantia nigra.
Symptomatic treatment is efﬁcacious, but there are
currently no drugs that demonstrably slow the
disease course. It is believed, albeit not proven, that
pathology may be too far advanced at the point of
clinical diagnosis to be affected by potentially neu-
roprotective treatments (assuming that these are
available). Identifying individuals at the earliest
stages of disease would pave the way for clinical
trials of emerging and repurposed drugs to prevent/
delay progression to clinically manifest PD (see
ﬁgure 1). However, modifying risk in those that do
not yet have a diagnosis represents a challenge. The
terms ‘early disease’ or ‘at-risk’ are frequently used
synonymously due to uncertainty about the point
at which the pathological process starts, but clariﬁ-
cation will be important since it will determine
whether prevention is attempted on a primary or
secondary basis, and factors that initiate pathology
may not necessarily be the same as those that
subsequently drive progression. Inability to identify
disease activity before diagnosis precludes distinc-
tion of the two, but this limitation may be over-
come, given current momentum in the ﬁeld of
biomarkers.
In this review, we describe current knowledge
and emerging ﬁndings in the prediagnostic phase of
PD, including early features, genetic and environ-
mental risk and protective factors, discuss current
strategies to identify individuals at earliest disease
stages to include in future clinical trials, and high-
light how the knowledge gleaned from these
studies might bridge the gap into preventive or pro-
tective drug trials for PD.
IDENTIFICATION OF INDIVIDUALS AT THE
EARLIEST STAGES
Genetic factors
Having a family history of PD increases the odds of
PD by 3–4.5-fold, and up to 10% of patients
report a family history of PD.1 Studies into the
genetic basis of PD implicate lysosomal and mito-
chondrial dysfunction, and inﬂammation in patho-
genesis.2 3 Of the conﬁrmed monogenic forms of
PD, most result in abnormalities of one or more of
these processes, but most are exceedingly rare and
do not account for elevated risk at a population
level (see ﬁgure 2). A central player in the disease is
α-synuclein and mutations in the SNCA gene,
which encodes this protein, are a cause of familial
PD. Intraneuronal accumulation of α-synuclein is
the pathological hallmark of PD, and mounting evi-
dence suggests that ﬁbrillar and oligomeric forms
of the protein may be neurotoxic.4 5 The full
picture of how these complex processes combine to
result in neurodegeneration remains incomplete,
but current theories include the possibility of prion-
like cell-to-cell propagation.6
Mutations in the LRRK2 gene are the commonest
known genetic cause for PD, and the G2019S
mutation occurs in 4% of hereditary and 1% of
sporadic PD.7 LRRK2-related disease has age-
dependent penetrance (28% at 59 years, 51% at
69 years and 74% at 79 years), meaning that only a
proportion of carriers will develop PD during life.7
LRRK2 mutation carriers have been shown to have
subclinical dopaminergic abnormalities, measured
with functional imaging, and higher rates of non-
motor features of PD than non-carriers.8 9 In
patients with PD and LRRK2 mutations, the motor
picture may be similar to idiopathic PD, but wider
manifestations may not be.7 8
Heterozygous mutations in the glucocerebrosi-
dase (GBA) gene are associated with an increased
risk of PD. Large studies have shown that GBA
mutations are common in Ashkenazi Jews,
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occurring in 15% of patients and 3% of controls.10 In unse-
lected patients with PD, 3.5% carry disease-associated GBA
mutations compared with <1% of controls.10 11 Clinical fea-
tures of patients with PD and GBA mutations may be similar to
sporadic PD and generally respond to levodopa, but onset of
parkinsonism can be earlier, and carriers tend to have higher
rates of cognitive problems and R(apid)E(ye)M(ovement) sleep
behaviour disorder (RBD).11 Furthermore, early non-motor fea-
tures of PD such as depression, subjective RBD and olfactory
dysfunction have been observed in carriers of GBA mutations
without PD, when compared with healthy controls.12
The study of manifesting and non-manifesting carriers of
LRRK2 and GBA mutations is important for understanding the
prodromal phase of PD, and for studies of drugs targeting spe-
ciﬁc pathways. Cohorts of these subjects have been assembled to
fulﬁl these aims, but with greater study, further differences may
emerge between PD related to these mutations and sporadic
disease. Other examples of monogenic PD include mutations,
duplications and triplications of the SNCA gene causing domin-
antly inherited PD, and mutations in PARK2, PINK1 and DJ1
causing recessively inherited forms of PD (for review see ref. 3),
with more emerging gradually. These monogenic causes of PD
are too rare to base predictive studies on, but they give import-
ant insight into disease mechanisms and therapeutic targets.
Mutations in single genes do not account for all the heritable
risk apparent in complex diseases, and genome-wide association
studies, in which large numbers of unrelated cases are compared
with unrelated controls, have yielded informative results. There
are at least 28 independent risk variants associated with PD that
increase or decrease risk in a small but potentially additive
way.13 This enables the construction polygenic risk proﬁles,
pooling the combined effect of multiple variants to estimate risk
of PD or indeed age of disease onset.14 15 However, the herit-
able component of PD is estimated to be greater still, at around
30%, and identiﬁed risk loci and monogenic forms explain only
about 5–10%.16 Over time, with increasing numbers of studied
cases and controls, along with deep resequencing and precision
phenotyping, a greater proportion of the heritability of PD will
be uncovered. The inﬂuence that genetic variation has on PD is
not limited to risk of getting disease alone, and speciﬁc variants
are likely to contribute additionally to age of disease onset, pro-
gression and phenotype, with a number of indicative studies
reported thus far.11 17 Furthermore, these and additional genetic
factors may dictate therapeutic choices in the future in the clin-
ical setting and in terms of recruitment to clinical trials. The
genetic architecture of PD is continually expanding and increas-
ingly complex. It has implications for multiple aspects of the
disease, but other factors are also important in determining risk.
Environmental risk factors
There is a large body of evidence demonstrating a small but sig-
niﬁcantly elevated risk of PD associated with a number of envir-
onmental risk factors (see ﬁgure 2). Some of the strongest
environmental evidence exists for exposure to pesticide and
proxies for this, including farming occupation, rural living and
drinking well water.1 Speciﬁc implicated pesticides include rote-
none and paraquat (structurally related to 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), which has also been linked
to parkinsonism in users of illicit drugs18), and both these che-
micals are used to create animal models of PD. Other potential
toxins include heavy metals such as manganese, with exposure
arising through occupations such as welding and in recreational
ephedrone users.19 It seems unlikely that environmental toxins
play more than a minor role in PD risk overall, with
meta-analysis suggesting ORs in the region of 1.2–2.0.1
Pooled observational study data also implicates head injury as
a minor but signiﬁcant risk factor for PD.1 20 There is increasing
evidence that individuals who suffer recurrent head injury, par-
ticularly sportspersons such as boxers, jockeys, American foot-
ball and rugby players, are at risk of developing a range of
degenerative neurological conditions including parkinsonism,
dementia and motor neuron disease, although pathological
examination of these subjects tends to reveal alternative path-
ology than that typically associated with PD.21
By stark contrast with other common chronic diseases, there
exist a number of intriguing but consistent negative associations
with PD and lifestyle factors such as smoking, caffeine and
alcohol.1 Additionally, there are a number of medications for
which negative associations with PD have been reported in
observational studies, including calcium channel blockers,
non-steroidal anti-inﬂammatories and statins.1 Some of these are
Figure 1 A schematic depicting normal (black solid line) and
Parkinson’s disease-related (grey solid line) nigral cell loss over time,
including the point at diagnosis typically occurs (horizontal black
hashed line) and the potential for modifying the trajectory of
degeneration, if identiﬁed earlier (hashed grey line). NB. For colour
version grey lines appear red, black lines remain black.
Figure 2 Risk factors and early features of Parkinson’s disease
associated with increased (or decreased) risk of subsequent diagnosis.
Estimated magnitude of effect is plotted against estimated frequency.
SN+ is hyperechogenicity in the region of the substantia nigra using
transcranial sonography. Genetic and environmental risk factors are
shown in lighter grey, and prediagnostic features and hyperechogenicity
in darker grey. NB. For colour version genetic factors are red,
environmental factors are orange, pre-diagnostic features are green and
imaging features are blue.
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currently the focus of clinical trials examining their potential
use in PD.
Whether these exposures offer true neuroprotective properties
or whether negative association, at least with lifestyle factors,
arises due to a common feature (eg, avoidance as part of an early
PD personality change) is yet to be determined. The former pos-
sibility is supported by clinical studies reporting improvement of
motor function in a clinical trial of caffeine to treat excessive
daytime somnolence in PD and PD animal models that show
protective effects of nicotine on nigrostriatal damage.22 23
Spurious association may arise as a result of reverse causality, a
potential problem with observational studies. This may be plaus-
ible even in prospective studies that exclude cases of incident PD
in the ﬁrst few years of follow-up because the prodromes of PD
are likely to be very long, during which time pathology is
present, but the classical features are not yet overt.
Another consistent negative association exists between levels
of serum urate and PD, with a number of studies demonstrating
a ‘protective’ effect of elevated serum urate.1 The most recent
of these studies is an example of Mendelian randomisation
(MR), which is a powerful technique to assess casual relation-
ships between risk factors and disease. In MR studies, a gene
variant is used as a proxy for an environmental exposure (or
intermediate phenotype), to determine the effect of this on a
disease outcome. Simon and colleagues used single nucleotide
polymorphisms in the SLC2A9 gene (which explain a propor-
tion of the genetically speciﬁed variability in serum urate) to test
whether these polymorphisms predicted rate of progression in
early PD. They demonstrated that SLC2A9 status was associated
with elevated serum urate and was associated with slower
disease progression.24 The MR approach is protected against
biases that can arise in traditional observational studies assessing
causation; if, for example, reduction in serum urate occurred as
an early consequence of PD, a spurious negative association
between the exposure and outcome might arise. MR on the
other hand operates more like a randomised controlled trial in
which the exposure (in this case a gene variant) is randomly
allocated at baseline (conception) along with known and
unknown confounding factors. Given the consistency of this
relationship in the MR study with previous observational
studies, therapeutic modulation of urate levels is a strong target
for clinical trials.
Increasing research activity in exploring the overlap between
genes and the environment will further our understanding of
the causal basis of disease. As for many diseases, the total
picture of risk remains incomplete due to apparent and substan-
tial randomness of the onset, the obscuration of risk factors
either because of rarity, ubiquity or poor measurement, or the
fact that disease tends to strike those at moderate risk, simply
because those at ‘highest risk’ are far fewer.
Early clinical features
Recognition of the importance of non-motor features of PD has
been building for several years.25 26 In established PD, patients
regard non-motor symptoms at least as troublesome as motor
features, and treatment is often difﬁcult.27 Non-motor symp-
toms are experienced early and there is substantial evidence
which suggests that they also predate diagnosis by several years
(see ﬁgure 2). A number of studies have demonstrated the asso-
ciation of PD with earlier diagnoses such as depression, anxiety,
constipation and erectile dysfunction.1 28 29
The best characterised early non-motor features are idiopathic
anosmia and RBD. Anosmia is relatively common in the ageing
population and is non-speciﬁc, with only a proportion going on
to develop neurodegenerative disease.30 RBD on the other
hand, is relatively speciﬁc for neurodegeneration, with high con-
version rates, but clinical and pathological heterogeneity in that
it can precede PD, dementia with Lewy bodies and multiple
system atrophy.31 An important distinction lies between subject-
ive RBD (on clinical history or questionnaire-based diagnosis)
and that which is formally diagnosed with an overnight sleep
study and polysomnography (PSG). PSG-conﬁrmed RBD is rare
in the general population, and the largest observational study
amassed just over 300 subjects despite international collabora-
tive efforts.32 Nonetheless study of PSG-conﬁrmed RBD has
resulted in positive strides forward given that time during which
a proportion will convert to neurodegenerative disease is known
(25% at 3 years and 40% at 5 years).32 The emergence of
anosmia or subtle motor signs, in particular, in those with RBD
appears to further reﬁne estimates of those that are likely to
convert.33 34
Characterisation of non-motor features is potentially valu-
able for early identiﬁcation of PD and the Movement
Disorders Society (MDS) has recently released Research
Criteria for Prodromal PD.35 The literature initially described
the early phase of PD as being the ‘pre-motor’ phase, but
more recently this has fallen out of favour with the recogni-
tion that subtle motor features can be present before diagno-
sis.28 36 The clinical diagnosis of PD requires multiple motor
features to be established, and while subtle motor signs may
be present, a clinical diagnosis of PD cannot be made until
they become more deﬁnite.4 Given that subtle or single motor
abnormalities occur prior to diagnosis and alongside early
non-motor features, this period is better referred to as the
prediagnostic phase.28 The MDS recommends the following
terminology:35
1. Preclinical PD—presence of neurodegenerative synucleinopa-
thy without clinical symptoms (this stage will be deﬁned by
disease biomarkers when available).
2. Prodromal PD—presence of early symptoms and signs
before PD diagnosis is possible.
3. Clinical PD—diagnosis of PD has been made based on the
presence of classical motor signs.
The emergence of large longitudinal primary care datasets has
allowed detailed exploration of the full range of early motor
and non-motor symptoms that predate PD, while being free
from the biases that many traditional observational studies have
suffered from.28 Alongside, advances in wearable technology,
and the availability of remote testing, will aid objective measure-
ment of emerging motor dysfunction in those at risk of PD.37 A
variety of measuring devices have been developed, including
software applications which harness information on activity and
motion (and in some cases speech) captured by smart phones
and tablet-devices, custom-built sensors that measure gait, bra-
dykinesia, dyskinesia and nocturnal movements, keyboard-based
speed and accuracy tests, as well as custom-built home-testing
devices (for examples of these, see online supplementary
material). Many of these devices demonstrate high sensitivity
and speciﬁcity in differentiating patients with PD from controls,
and are likely to see increasing use in clinical practice to guide
decision-making. Despite the indication that objective motor
dysfunction occurs prior to diagnosis in PD, currently there are
few examples of the application of remote or wearable devices
in prediagnostic PD. A major foreseeable hurdle is ensuring that
validation and regulatory approval for software and devices will
keep abreast of rapid and continuous change in available
technology.38
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Imaging markers
Radiotracer imaging with single photon emission computed
tomography (SPECT) or positron emission tomography (PET),
and transcranial sonography (TCS) have repeatedly demon-
strated the ability to differentiate patients with PD from healthy
individuals with adequate sensitivity and speciﬁcity (see table
1).39 These modalities may also have the potential to identify
subclinical PD prior to diagnosis, and early support for this
notion came from studies showing that SPECT and PET were
typically abnormal bilaterally in patients with unilateral PD, and
could identify unaffected twins of patients with PD who later
went on to develop PD.39 Using SPECT, the clinical diagnosis of
PD tends to be made once there has been 40–50% reduction in
tracer binding and an average 11.2% decline in striatal binding
has been observed each year after diagnosis.39 Multitracer PET
has also shown deterioration over time in patients with estab-
lished PD, but is expensive when considering use on a large
scale.40
Evidence of demonstrable longitudinal change using DaT
(dopamine transporter) SPECT in early PD is now being sought
with serial studies performed as part of the Parkinson’s
Progression Markers Initiative (PPMI) study.41 Furthermore,
progressive change in SPECT imaging has been reported in a
study of patients with RBD, and in the Parkinson’s At Risk
Study (PARS), which includes subjects with idiopathic anosmia
(and other prodromal markers).42 43
By contrast, TCS demonstrating hyperechogenicity of the sub-
stantia nigra (SN) appears to be a static rather than changing
marker.39 A study in individuals with mild parkinsonian fea-
tures, found a sensitivity of 91%, speciﬁcity of 82% and positive
predictive value (PPV) of 93% for SN hyperechogenicity and
PD diagnosis after follow-up, despite blinding those performing
sonography to clinical details at baseline.44 Current efforts to
improve standardisation and quantitative analysis for TCS and
SPECT may increase their utility in the prediagnostic phase of
disease, with SPECT more likely to demonstrate sensitivity to
change.
High-ﬁeld and novel sequences of MRI may also provide
opportunities to address the challenge of imaging disease pro-
gression in the prediagnostic phase of PD. Correlations of MRI
microstructural imaging abnormalities have been reported with
postmortem ﬁndings and quantitative differences between
patients with PD and healthy subjects in terms of iron depos-
ition, loss of neuromelanin and alterations in nigrosome 1, in
mainly single studies (for examples see online supplementary
material). In addition to subtle structural abnormalities, applica-
tion of functional MRI methods have shown differences in func-
tional connectivity with the basal ganglia network, the
default-mode network and the sensorimotor resting state
network, between patients with PD and healthy controls, some
of which are inﬂuenced by dopaminergic medication (see online
supplementary material for examples of studies).
123I-meta-iodobenzylguanidine (MIBG) myocardial scintig-
raphy has been largely studied in Japan, with multiple reports
showing a reduction in heart to mediastinum ratio of MIBG
uptake in patients with PD, compared with healthy controls or
other degenerative causes of parkinsonism.45 Cardiac sympa-
thetic nerve involvement is a feature of incidental Lewy body
pathology, which is believed to be the pathological precursor to
PD.46 Altered MIBG uptake has been reported in patients with
a range of early non-motor features of PD, including autonomic
dysfunction, mood disorders and sleep disorders, meaning that
it may be a good prediagnostic imaging marker for PD, but
further studies are required.47
Fluid and tissue biomarkers
Given the supposed central importance of α-synuclein to the
disease process, recent biomarker strategies have centred on
ﬁnding and characterising forms of the protein in a range of
bioﬂuids and tissues. Blood has been a disappointing target
to-date because red cells contain large quantities of α-synuclein,
obscuring any theoretical difference in levels between patients
and controls, but some group differences have been demon-
strated for DJ-1, urate, vitamin D and IGF-1 (for examples of
individual studies see online supplementary material).48 Plasma
apoliprotein A1 has been shown to differentiate patients from
healthy controls and, interestingly, also to correlate with DaT
SPECT deﬁcit in hyposmic subjects with a family history of PD,
recruited from the PARS study.49
It is believed that cerebrospinal ﬂuid (CSF) is most likely to
show changes representative of disease occurring in the brain.
Nonetheless, lumbar puncture is an invasive and costly proced-
ure compared with blood draw, and is likely to remain most
appropriate for use in clinical trials and in speciﬁc clinical prac-
tice settings, unless a high-performing biomarker can be identi-
ﬁed. Potential CSF biomarkers for PD include α-synuclein and
DJ-1, with Aβ42 potentially correlating with cognitive impair-
ment, and various forms of tau protein and neuroﬁlament light-
chain differentiating PD from atypical parkinsonian disorders.50
Separately, observed biomarker changes in saliva have included
Table 1 Imaging modalities and markers for Parkinson’s disease
Modality Example tracers/sequence Observation(s) Analysis Accessibility Cost
Suitability
for screening
SPECT 123I-β-CIT
123I-FP-CIT
Loss of binding in striatum Visual inspection, quantification ++ +++ +++
TCS 2–3.5 Hz transducer Hyperechogenicity in the region of
the substantia nigra
Visual inspection, quantification ++++ + +++
PET 18F-dopa
18F-FDG
Loss of binding in striatum
May help differentiate atypical PD
Visual inspection, quantification ++ ++++ +
MRI Traditional (T1& T2), T2/T2*
(gradient echo), DTI, spin
echo, fMRI
Numerous reported, none
established
Visual inspection, quantification +++ ++ ++
MIBG 123I-meta-iodobenzylguanidine Low heart-to-mediastinum ratio Visual inspection, quantification ++ ++ ++
Accessibility, cost and suitability for screening are estimated semiquantitatively on a four-point relative scale with + lowest and ++++ highest.
DTI, diffusion tensor imaging; FDG, fludeoxyglucose; fMRI, functional MRI; Hz, hertz; MIBG, metaiodobenzylguanidine; PET, positron emission tomography; SPECT, single photon
emission computed tomography; TCS, transcranial sonography.
4 Noyce AJ, et al. J Neurol Neurosurg Psychiatry 2016;0:1–8. doi:10.1136/jnnp-2015-311890
Movement disorders
group.bmj.com on March 11, 2016 - Published by http://jnnp.bmj.com/Downloaded from 
reduction in α-synuclein levels and elevation of DJ-1 in the
saliva (see online supplementary material for examples of indi-
vidual studies of CSF and salivary biomarkers).
α-Synuclein pathology is found outside the central nervous
system in patients with PD (even preceding diagnosis in some
instances), using a variety of sampling methods, immunohisto-
chemical techniques, in fresh and archival tissue. The gut has
been proposed as the site of initiation of PD pathology, but the
burden of synucleinopathy correlates poorly with disease sever-
ity and the proximal (more) to distal (less) gradient in pathology
appears at odds with this suggestion.51 52 In addition, there is
variability in the reporting of cell loss and a current lack of con-
sensus of what should be classiﬁed as Lewy pathology given that
the appearances in gut are dissimilar to what is seen typically in
the brain of patients, and the fact that control subjects have vari-
able staining for α-synuclein.53 The potential for gut biomarkers
remains high, however, and may not be restricted to tissue sam-
pling. Recently, interest has been stirred by demonstrable differ-
ences in the faecal microbiome of patients and controls.54
Salivary glands may also be a peripheral source for demon-
strating PD-related pathology but, like gut biopsies, the invasive
nature and cost of deep tissue sampling or full colonoscopy cur-
rently make both undesirable.52 55 Of signiﬁcant interest is a
recent study showing synuclein deposition in dermal punch
biopsies taken from patients with PD, and differentiating these
subjects from other forms of parkinsonism.56 While these ﬁnd-
ings require replication, the skin offers the exciting possibility of
yielding biomarkers for PD, and is signiﬁcantly more accessible
than salivary glands and the gut. A summary of tissue and ﬂuid
biomarkers is provided in table 2.
CURRENT STUDIES MAPPING THE PREDIAGNOSTIC AND
PERIDIAGNOSTIC PHASES OF PD
Several studies (table 3) have been initiated: to identify those in
the prediagnostic and prodromal phases of PD; identify clinical
and biological markers to track progression of disease before
diagnosis; create platforms to ﬁnd subjects for inclusion in neu-
roprotective drug trials. As outlined above, some initiatives
recruit individuals with a single strong risk factor such as carrier
status for LRRK2 or GBA mutations, or idiopathic RBD or
anosmia, in order that subjects may be followed prospectively,
whereas other approaches employ large population-based
cohorts or retrospective case–control methods to examine asso-
ciations with PD and preceding diagnoses. From the former we
learn more about the emergence of PD in speciﬁc risk cohorts,
which, in turn, may prove to be appropriate for recruitment to
clinical trials. They are likely to be more homogenous in terms
of their disease mechanisms, pathology and clinical features, as
well as being the simplest in which to determine ‘time to
conversion’. However, they are perhaps not representative of
the spectrum of PD as a whole, and biomarkers developed in
these groups must be replicated in sporadic PD cohorts before
assuming that they are applicable to all. The latter are difﬁcult,
and costly to conduct with in-depth assessments and appropriate
sample sizes, but allow the investigation of risk/protective
factors and early symptoms and signs that precede emergence of
established PD. This, in turn, informs strategic combination of
factors to try and delineate individuals at high risk while also
capturing the full spectrum of PD. Although the magnitude of
risk associated with individual risk factors and early non-motor
features has been reported, the best combination of risk factors
for predicting PD remains unknown.1 35 Several studies are now
seeking to combine risk factors for PD in order to improve pre-
dictive power with which those at increased risk of PD can be
identiﬁed, with and without imaging markers.
The Prospective validation of Risk factors for the develop-
ment of Parkinson Syndromes (PRIPS) study was a large pro-
spective study that sought to determine the magnitude of risk of
PD that SN hyperechogenicity conveyed.57 Over 1800 partici-
pants were screened and 304 had hyperechogencity. At 3 years
follow-up, 11 had developed PD and the relative risk of incident
PD was 17.3 (95% CI 3.7 to 81.3) if there was SN hyperecho-
genicity at baseline.57 The aforementioned PARS study uses
objective smell testing to identify subjects with idiopathic
anosmia at stage 1, followed by DaT SPECT at stage 2 to iden-
tify subclinical presynaptic denervation.43 The study has
reported early results which demonstrated reductions in nigros-
triatal DaT binding in subjects with hyposmia compared to
those with normal smell, as well as associations between a
number of prodromal features of PD within the study cohort.43
The Tübinger evaluation of Risk factors for the Early detection
of NeuroDegeneration (TREND) study examines subjects who
are over 50 years of age, with a limited combination of risk
factors (anosmia or depression or RBD), using serial studies of
movement, laboratory tests and imaging, with follow-up to inci-
dent PD. Baseline data from this cohort have been reported
showing associations between selected prodromal markers and
other early associated features of PD.58
Two large multicentre studies, one coordinated from the USA
(the Parkinson’s Progression Markers Initiative, PPMI) and one
based in the UK (the Tracking Parkinson’s or PRoBaND study),
recruit patients immediately after the clinical diagnosis of PD
and undertake detailed clinical, imaging and biomarker studies
longitudinally. While not strictly looking at prediagnostic PD,
the PPMI and PRoBaND studies will help deﬁne the role of
clinical markers (motor and non-motor) in the early measure-
ment of PD, and the identiﬁcation of novel imaging and labora-
tory biomarkers, as well as giving insight into what might be
Table 2 Tissue and fluid biomarkers for PD
Source Medium Main techniques Candidate markers Invasiveness Cost
Suitability
for screening
Cerebrospinal fluid Fluid Assay, electrophoresis, mass-spec t-α-syn, p-α-syn, t-tau, p-tau, NFL +++ ++ ++
Blood Fluid Assay, electrophoresis, mass-spec Uric acid, inflammatory markers, IGF-1, ApoA1, DJ-1 ++ + +++
Saliva Fluid Assay, electrophoresis, mass-spec α-syn, DJ-1 + + +++
Gut Tissue biopsy Immunohistochemistry t-α-syn, p-α-syn ++++ +++ ++
Salivary gland Tissue biopsy Immunohistochemistry t-α-syn, p-α-syn ++++ +++ +
Skin Tissue biopsy Immunohistochemistry t-α-syn, p-α-syn +++ ++ +++
Invasiveness, cost and suitability for screening are estimated semiquantitatively on a four-point relative scale with + lowest and ++++ highest.
ApoA1, apolipoprotein A1; IGF-1, insulin like growth factor 1; NFL, neurofilament light chain; p-α-syn, phosphorylated α synuclein; t-α-syn, total α synuclein.
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apparent through back-extrapolation to the prediagnostic phase.
The PPMI study also includes a prodromal arm (P-PPMI) in
which subjects with RBD, anosmia or a mutation (LRRK2, GBA
or SNCA), will be assessed and followed in the same way as PD
subjects, allowing for a seamless examination of the prediagnos-
tic and early disease stages of PD. Separately, as part of a large
study aimed at understanding the biological basis of disease in
patients with established PD, the Oxford Parkinson’s Disease
Centre (OPDC) includes smaller ‘high-risk groups’ with a family
history or RBD. Clinical assessments, laboratory and imaging
biomarker studies are being undertaken and early results are
emerging.59
In the UK, the PREDICT-PD study combines risk factors and
early non-motor features to devise a risk scoring process for
future PD. Risk scores were calculated based on a meta-analysis
of the published literature.1 These, in turn, were used to gener-
ate ORs for the effect on risk of PD ascribed by individual early
non-motor features and risk factors. Using a priori odds of PD
attributed to age, a Bayesian model of risk was constructed to
yield combined risk estimates for each subject in the study.60
The study runs almost entirely via the internet with more
detailed laboratory, motor and imaging investigation for groups
at the extremes of risk. PREDICT-PD is the ﬁrst study to try
and combine large numbers of risk factors for PD and has the
potential to screen a large, community-based population, and
aims to facilitate recruitment into clinical trials in the future.
Unlike some of the other studies, it seeks to identify individuals
spanning the full spectrum of PD, which makes this cohort
highly applicable to occurrence of typical PD in clinical settings.
FURTHER CHALLENGES AND OPPORTUNITIES IN THE
PREDIAGNOSTIC PHASE
The above studies aim to overcome the important challenge of
identiﬁcation of ‘at-risk’ individuals who may develop the
Table 3 Studies in the prediagnostic phase of Parkinson’s disease
Acronym Study name Participants Country
Number
recruited Tests/exposures Outcome
PRIPS57 Prospective validation of risk
factors for the development of
Parkinson syndromes
Subjects over 50 years old Germany,
Austria
1847 TCS, smell, UPDRS Clinical diagnosis
of PD
TREND58 Tübinger evaluation of risk
factors for the early detection of
neurodegeneration
Subjects over 50 years with
anosmia, self-report RBD or
depression
Germany >1200 TCS, smell, UPDRS,
quantitative motor,
psychometry, blood
biomarkers
Clinical diagnosis
of PD
PARS43 Parkinson’s at-risk syndrom
study
Subjects over 50 years with
hyposmia and DaT deficit on
SPECT
USA 4999 (completed
baseline smell
test)
Smell, DaT SPECT, UPDRS,
cognition, blood biomarkers
Clinical diagnosis
of PD/DaT deficit
on SPECT
P-PPMI41 Prodromal Parkinson’s
Progression Markers Initiative
Subjects with prodromal
features or gene mutations
International Anosmia/RBD=65
Genetic=150
CSF and blood biomarkers,
UPDRS, cognition, sleep and
autonomic assessments
Clinical diagnosis
of PD
OPDC59 Oxford Parkinson’s Disease
Centre study
Subjects with a first-degree
relative with PD, or subjects
with RBD (PSG confirmed)
UK ∼190 UPDRS, non-motor
assessments, blood and CSF
biomarkers
Clinical diagnosis
of PD
PREDICT-PD60 PREDICT-PD Subjects over 60 years old UK 1323 In all (online): risk scoring,
smell, RBDSQ, quantitative
motor (BRAIN test), genetics
In extremes of risk: UPDRS,
cognitive, TCS
Clinical diagnosis
of PD/DaT deficit
on SPECT
BRAIN test, BRadykinesia Akinesia INcoordination test; B-SIT, Brief Smell Identification Test; CSF, Cerebrospinal Fluid; DaT, Dopamine Transporter; PD, Parkinson’s disease; PSG,
polysomnography; RBD, REM sleep Behaviour Disorder; RBDSQ, RBD Screening Questionnaire; SPECT, single photon emission computed tomography; TCS, Transcranial Sonography;
UPDRS, Unified Parkinson’s Disease Rating Scale.
Figure 3 A schematic showing
determinants of risk, the prediagnostic
phase (preclinical and prodromal
phases) and clinical phase of
Parkinson’s disease, along with the
parallel application of risk and disease
progression markers to measure
disease activity across phases.
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classical clinical syndrome of PD, with the eventual aim of initi-
ating treatment to avoid or delay clinically relevant symptoms.
In addition, studies such as PPMI (with P-PPMI), TREND,
PARS and PREDICT-PD will document the time immediately
before, during and after the emergence of clinically recognisable
PD, delineating the clinical and biomarker features of this phase
that will be crucial to commencing clinical trials. These studies
will help reﬁne the determination of risk status and course of
early disease progression (see ﬁgure 3).
There are additional hurdles that must be overcome before
clinical trials recruiting subjects in this phase of disease can be
planned: (1) determination of appropriate study endpoints and
duration of trials. Prevention or delaying emergence of classical
symptom onset is the ultimate aim, but PD is insidious, with its
clinical manifestations emerging over months and years, making
many clinical end points unsuitable and such studies difﬁcult to
fund for the duration required. A sensitive clinical marker of
progression would be valuable in detecting subtle changes at
this early phase, however, an imaging or laboratory marker that
spanned the prediagnostic and early postdiagnostic phases may
offer better sensitivity, speciﬁcity, reliability and precision overall
(see ﬁgure 3). This, in turn, could allow appropriate calculation
of sample sizes and trial duration, dependent on anticipated
drug effect; (2) another important consideration in trial design
is the heterogeneity in clinical manifestation of PD, rate of pro-
gression and the presence/absence of other features. Clinical
trials designed to show the disease-modifying effect of an agent
may initially need to include homogenous samples or samples
stratiﬁed for presentation and rate of progression in order to
show an effect before trials in wider groups can be conducted;
(3) other factors are continuity and applicability through the
early stages of the disease. Even with an optimised early detec-
tion process, there will still be individuals who are ‘undetected’,
and ﬁrst present with overt signs of PD, and potential treat-
ments will need to be assessed for demonstrable effects in these
subjects too. Longer-term observational studies that examine
risk status could support registries through which subjects indi-
cate their willingness to participate in future clinical trials and
biomarker initiatives. Consenting eligible subjects could be
offered inclusion into clinical trials with the beneﬁt of extensive
available pre-trial data, but issues of selection bias and generalis-
ability of results must be considered; (4) Finally, there are
ethical implications of treating at-risk populations. For a repur-
posed drug, with previous data on safety and tolerance, the
implications of undertaking clinical trials in those at-risk are
perhaps less than for novel drugs with unknown safety proﬁles
and potential toxicity. Justiﬁcation for more invasive therapies
could probably not be found without clear results in established
PD. In addition, disclosure of risk status is likely to be a pre-
requisite for participation in clinical trials, but has the potential
to bias recruitment and poses an ethical barrier in the absence
of proven neuroprotective effects. Ultimately, disclosure may be
unavoidable in order to make an informed decision about trial
participation.
CONCLUSION
Signiﬁcant progress has been made in the understanding and
identiﬁcation of subjects in the prediagnostic phase of PD and a
number of initiatives are underway to further deﬁne these
groups. These studies may contain subjects that would be candi-
dates for recruitment into clinical trials targeting neuroprotec-
tion within a few years. Parallel exploration of peripheral tissue,
ﬂuid and multimodal imaging is needed to identify differences
between patients and controls across a range of markers. Of
major interest is whether these differences can be demonstrated
in high-risk/prediagnostic subjects, and whether they change up
to the point of diagnosis and immediately beyond. This will
enable testing of drug therapies at a time when more neuronal
tissue can potentially be preserved, and there is an absence of
symptomatic effects of medication with the potential to
confound.
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